Budget Impact Analysis of the Introduction of Subcutaneous Infliximab (CT-P13 SC) for the Treatment of Rheumatoid Arthritis in the United Kingdom

CT-P13 subcutaneous (SC)—the first and only SC version of infliximab—is approved by the European Medicines Agency for the treatment of rheumatoid arthritis (RA). This new mode of infliximab administration will allow patients to self-inject at home, significantly reducing the number of outpatient visits and costs of intravenous (IV) administration. This paper describes the economic impact of introducing CT-P13 SC to the market from the UK societal perspective. The budget impact analysis was conducted to assess the financial impact of the adoption of CT-P13 SC over a 5-year period. A prevalence-based budget impact model was developed incorporating epidemiological data, administration cost data, and market share data. The analysis compared a “world with” CT-P13 SC scenario to a “world without” CT-P13 SC. A sensitivity analysis included dose escalation up to 4.1 mg/kg to reflect the real-world care delivery setting. Compared to the “world without” scenario, the introduction of CT-P13 SC resulted in cost savings of ₤69.3 million in the UK over a 5-year period. In the scenario analysis, the saving increased to ₤173.5 million over 5 years. Use of CT-P13 SC may lead to substantial cost savings for the UK society.